Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Century Therapeutics (IPSC) EPS (Weighted Average and Diluted) (2022 - 2025)

Historic EPS (Weighted Average and Diluted) for Century Therapeutics (IPSC) over the last 4 years, with Q3 2025 value amounting to -$0.4.

  • Century Therapeutics' EPS (Weighted Average and Diluted) fell 810.81% to -$0.4 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.32, marking a year-over-year increase of 8270.27%. This contributed to the annual value of -$1.61 for FY2024, which is 3003.25% up from last year.
  • Century Therapeutics' EPS (Weighted Average and Diluted) amounted to -$0.4 in Q3 2025, which was down 810.81% from -$0.38 recorded in Q2 2025.
  • Over the past 5 years, Century Therapeutics' EPS (Weighted Average and Diluted) peaked at $0.89 during Q1 2025, and registered a low of -$1.24 during Q4 2022.
  • Moreover, its 4-year median value for EPS (Weighted Average and Diluted) was -$0.53 (2022), whereas its average is -$0.45.
  • Over the last 5 years, Century Therapeutics' EPS (Weighted Average and Diluted) had its largest YoY gain of 29760.29% in 2025, and its largest YoY loss of 810.81% in 2025.
  • Over the past 4 years, Century Therapeutics' EPS (Weighted Average and Diluted) (Quarter) stood at -$1.24 in 2022, then surged by 47.58% to -$0.65 in 2023, then grew by 29.44% to -$0.46 in 2024, then grew by 12.79% to -$0.4 in 2025.
  • Its last three reported values are -$0.4 in Q3 2025, -$0.38 for Q2 2025, and $0.89 during Q1 2025.